Book a Monoclonal Antibody Treatment

• What is Sotrovimab?

  Sotrovimab is currently the only monoclonal antibody proven to be effective against the Omicron variant. Monoclonal antibodies are laboratory-produced molecules engineered to serve as substitute antibodies that can restore, enhance, or mimic the immune system's attack on pathogens. Sotrovimab is designed to block viral entry into human cells, thus neutralizing the virus.

• Who should get Sotrovimab?

  Sotrovimab is authorized for emergency use by the FDA for the treatment of mild-to-moderate COVID-19 symptoms in adults with positive results of direct SARS-CoV-2 viral testing or for those at high risk for progression to severe disease. Receiving this infusion has shown to reduce the severity of symptoms associated with COVID-19, decrease hospitalizations, and mortality.

• When to get the Sotrovimab infusion?

  The EUA authorizes Sotrovimab to be administered by a qualified healthcare provider as a single intravenous infusion as soon as possible after positive viral test for COVID-19 and within 10 days of symptom onset.

• Does “within 10 days of symptom onset” mean that a patient should have shown symptoms to receive Sotrovimab for its treatment use?

  Yes. Symptom onset is the point at which a patient starts exhibiting symptoms. Patients should be treated as soon as possible after a positive viral test for SARS-CoV-2 and within ten days of COVID-19 symptom onset. If a patient has a positive viral test for SARS-CoV-2 but does not show symptoms, they do not meet the definition of mild-to-moderate disease.

• If i was in contact with someone who is Covid positive, can i get this infusion?

  No, the Sotrovimab monoclonal infusion is recommended for those who are currently experiencing mild to moderate symptoms and have tested positive for SARS-CoV-2